Previous 10 | Next 10 |
Arvinas (NASDAQ:ARVN): Q2 GAAP EPS of -$1.03 misses by $0.17. Revenue of $5.54M (-3.7% Y/Y) beats by $0.09M. Shares -1.73% PM. Press Release For further details see: Arvinas EPS misses by $0.17, beats on revenue
NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate ...
ARVN is a pioneering protein degrader biopharma with strong early data. Recently, Pfizer inked a $2bn deal with the company for just one of its assets. The stock looks very promising despite its 52-week highs. For further details see: Arvinas: Tremendous Value Increase W...
Koonsiri Boonnak/iStock via Getty Images GM (GM) took its turn in the spotlight during Friday's midday action. The carmaker announced a recall of its Chevy Volt electric vehicles due to fire concerns. Meanwhile, earnings news remained a key driver in intraday trading. Both South State (SSB) a...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
Shares of Arvinas (NASDAQ: ARVN) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (NYSE: PFE) . The two companies will co-develop and then co-market Arvinas' ARV-471, currently in trials as a ...
Arvinas (ARVN) perks up 3.8% premarket after collaborating with Pfizer (PFE) to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor ((ER)) protein degrader.Under the terms of the agreement, Pfizer will pay Arvinas $650M...
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2 development for the treatment of patients with local...
Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking c...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...